Is Your Clinical Laboratory Ready to Sell?

Engage a healthcare compliance firm to conduct an independent review of your CPT coding accuracy, claim submission practices, denial patterns, and any exposure to Medicare or Medicaid billing irregularities. Buyers will scrutinize your OIG and CMS audit history, and any unresolved billing issues found during due diligence will either kill the deal or result in a significant escrow holdback. Resolving these proactively removes the single biggest liability concern acquirers have when buying a clinical lab.

Verify that your CLIA certificate is active, that all required personnel qualifications are documented, and that your CAP accreditation is up to date with no outstanding corrective action items. Review your state laboratory licensure status in every jurisdiction where you accept specimens. Understand the change-of-ownership (CHOW) notification requirements for CLIA and begin mapping out the transfer process so it does not become a closing bottleneck.

Search the OIG exclusion database for your entity and all key personnel, including your lab director and billing staff. If there are any open audits, repayment demands, or prior settlements, engage healthcare counsel to resolve or formally document resolution status before going to market. Buyers will not proceed — or will demand significant indemnification — if unresolved regulatory matters exist at the time of diligence.

Audit all arrangements with referring physicians, mobile phlebotomy contractors, and patient service center partners to ensure compliance with the Stark Law and Anti-Kickback Statute. Specimen referral arrangements are a primary area of regulatory scrutiny in lab acquisitions. Document that all compensation arrangements are at fair market value and that no improper remuneration exists in exchange for referrals.

Work with a CPA experienced in healthcare services to convert your financials to accrual-basis accounting if you have been reporting on a cash basis. Prepare income statements, balance sheets, and cash flow statements for the trailing three fiscal years. Buyers — particularly those using SBA financing — will require reviewed or audited financials, and lenders will not issue term sheets based on cash-basis or tax-return-only reporting.

Create a revenue schedule that breaks down gross and net collections by test category (e.g., routine chemistry, toxicology, molecular diagnostics, anatomic pathology) and by payer class (Medicare, Medicaid, commercial insurance, self-pay, and direct bill). Buyers need to understand your exposure to PAMA-driven CLFS rate compression on high-volume routine tests versus your mix of higher-margin specialty or esoteric assays. This analysis directly informs their earnings sustainability assessment.

Work with your advisor to identify and document all legitimate owner add-backs: above-market owner compensation, personal vehicle expenses, personal insurance premiums, one-time legal or consulting fees, and any personal expenses run through the business. Create a formal seller's discretionary earnings (SDE) or adjusted EBITDA schedule with written support for each add-back. Unsupported add-backs will be challenged during diligence and removed from the buyer's valuation model.

Calculate and document your denial rate, clean claim rate, days sales outstanding (DSO), and net collection ratio for each of the past three years. Benchmark these against industry standards: best-in-class independent labs target DSO below 45 days and denial rates below 5%. If your revenue cycle metrics are lagging, engage a billing consultant to remediate before going to market, as poor RCM performance is a direct valuation discount.

If you own the real estate used by your lab or lease it from a related party, document the arrangement clearly and ensure the lease rate reflects fair market value. Buyers using SBA or conventional financing will require a formal lease agreement at market terms. Ambiguous facility arrangements create valuation confusion and financing complications. Decide early whether you intend to sell or lease the real estate as part of the transaction.

Pull every active payer contract — Medicare, Medicaid managed care, and commercial insurers — and review each for change-of-ownership assignment requirements, termination triggers, and notification timelines. Some payer contracts require 90–180 days advance notice of ownership changes and may not be automatically assignable. Identify any contracts that require payer consent to assign and begin mapping out the notification strategy so there are no surprises post-LOI.

Build a referring provider report showing specimen volume and net revenue attributable to each ordering physician group, urgent care network, hospital, or other referral source over the past three years. Flag any account representing more than 15–20% of total volume as a concentration risk. Buyers will view excessive concentration — particularly where the owner maintains the personal relationship — as a significant valuation risk. Document relationship tenure and, where possible, institutional rather than personal drivers of loyalty.

Identify the percentage of your net revenue derived from tests subject to ongoing PAMA-driven CLFS rate reductions. Quantify the projected revenue impact of known future rate cuts. If you have the capability, begin marketing specialty or esoteric tests — such as molecular panels, toxicology confirmation testing, or rare disease assays — to improve your revenue mix ahead of sale. Buyers heavily discount labs with high exposure to routine test reimbursement compression.

Where possible, formalize informal referral relationships into written service or preferred provider agreements with your top five to ten referring accounts. These do not need to be exclusive arrangements — simply documented, professional agreements that confirm the relationship, turnaround time commitments, and pricing terms. Written agreements provide buyers with contractual evidence of recurring volume that supports their earnings retention assumptions.

The lab director's qualifications and continued employment are non-negotiable for maintaining CLIA certification through a change of ownership. Execute a written employment agreement or retention arrangement with your lab director covering at least 24 months post-close. Identify other critical personnel — medical director, senior medical laboratory scientists, billing manager — and implement retention bonus structures or employment agreements funded at or before closing to reduce key-person departure risk.

If your referring physicians call your personal cell phone, attend events with you specifically, or have stated they refer because of their relationship with you personally, take deliberate steps to transfer those relationships to your lab director, client services team, or a dedicated sales liaison. Introduce key accounts to other members of your team over the 12–18 months before sale. Buyers will apply a steep discount if they believe volume will walk out with the seller.

Create a detailed inventory of all diagnostic analyzers, instrumentation, and laboratory equipment including purchase date, acquisition cost, current book value, remaining useful life estimate, lease or ownership status, vendor service agreement terms, and calibration and maintenance logs. Buyers and their lenders will require this documentation. Equipment in poor condition or nearing end-of-life will result in a direct capex deduction from enterprise value in negotiations.

Document your laboratory's standard operating procedures covering specimen intake, test processing workflows, quality control protocols, billing submission processes, and client service procedures. An SOP manual demonstrates that the business is operationally self-sustaining and not dependent on the owner's tribal knowledge. Buyers — particularly PE firms and first-time healthcare operators — place significant value on documented processes when assessing post-acquisition operational continuity.

For any analyzer or major piece of diagnostic equipment within 18–24 months of end-of-service-support or lease expiration, evaluate whether it is worth refreshing before sale. In some cases, a modest capital investment to replace aging equipment — particularly if the manufacturer has announced end-of-life — will generate a dollar-for-dollar reduction in buyer capex demands and prevent a valuation discount that exceeds the cost of the upgrade.

Retain an M&A advisor or business broker with demonstrated experience in clinical laboratory and healthcare services transactions. Lab deals require advisors who understand CLIA change-of-ownership mechanics, payer contract assignment risk, and how to position compliance history and revenue mix to the right buyer universe — which includes PE-backed roll-ups, hospital systems, pathology management companies, and SBA-financed operators. A generalist broker unfamiliar with healthcare will undervalue your lab and attract unqualified buyers.

Work with your advisor to build a CIM that tells the story of your lab's clinical capabilities, regulatory standing, referral network depth, payer contract quality, and revenue cycle performance. Lead with your specialty testing capabilities, CAP accreditation, and compliance clean bill of health. Include your equipment inventory summary, staff credentials, and EBITDA bridge. A well-constructed CIM accelerates buyer due diligence and reduces the length — and cost — of the diligence process.

Before receiving any offers, work with your advisor and CPA to model your after-tax net proceeds under different deal structures: asset purchase versus stock purchase, all-cash at close versus seller financing versus earnout, and escrow holdback scenarios tied to payer assignment or compliance milestones. Know your minimum acceptable price and preferred structure before entering negotiations so you can evaluate LOIs with clarity rather than emotion.

Develop a communication plan for informing your lab director and critical staff about the pending ownership transition. Timing is critical — too early risks operational disruption, too late can feel like a surprise that triggers resignations. Work with your advisor on the right moment to disclose, ideally after executing an LOI and confirming buyer seriousness. Have retention packages ready to offer at the time of disclosure to convert potential anxiety into commitment.